[{"id":"imerge-ep1","name":"RBC transfusion independence >=8 weeks","type":"PRIMARY","unit":"%","p_value":"<0.001","results":[{"ci":"30.9-49.3","arm":"imerge-imet","label":"39.8% (95% CI: 30.9-49.3)","value":39.8},{"ci":"7.1-26.6","arm":"imerge-pbo","label":"15.0% (95% CI: 7.1-26.6)","value":15}],"timepoint":"8 consecutive weeks","description":"Proportion of patients achieving red blood cell transfusion independence for at least 8 consecutive weeks. These are patients who previously needed regular blood transfusions (>=4 units every 8 weeks) - achieving 8 weeks without transfusion represents meaningful clinical benefit."}]

High rates of Grade 3-4 cytopenias: neutropenia 68% (vs 3% placebo), thrombocytopenia 62% (vs 8%). Cytopenias most frequent in cycles 1-3, generally manageable with dose modifications. ALT elevation 12% any grade (3% >5x ULN, same as placebo). No Hy's law cases. 16.1% discontinued due to AEs vs 0% placebo.

INVESTMENT RELEVANCE: Rytelo is a licensed EU product for SOBI (Geron holds US/ROW). Revenue depends on EU reimbursement timelines (country-by-country through 2026). Orphan exclusivity provides 10-year market protection. Key debate: can Rytelo differentiate vs luspatercept given the disease-modifying molecular response data? The 68% Gr3-4 neutropenia is the main clinical concern but manageable in hematology setting.

First-in-class telomerase inhibitor for lower-risk MDS with ring sideroblasts. Targets the root cause by depleting malignant hematopoietic stem cells that rely on telomerase for immortality.